BioNexus Gene Lab Corp announced that it has entered into an underwriting agreement with Network 1 Financial Securities, and under this agreement, the company issued and sold a total of 1,437,500 shares of common stock at a public offering price of $4.00 per share, earning total gross proceeds of $5.75 million. The underwriter also has the option to exercise warrants to purchase up to 115,000 shares of the company's common stock at an exercise price of $4.40 per share from July 24, 2023 to July 24, 2028.